Department of Pulmonary Diseases, VU University Medical Center, Amsterdam, The Netherlands.
J Thorac Oncol. 2009 Dec;4(12):1585-6. doi: 10.1097/JTO.0b013e3181bbb2b9.
Erlotinib is increasingly being used for the treatment of non-small cell lung cancer. The recommended dose is 150 mg/day and no efficacy data is available for lower doses. We describe a case of dramatic tumor response to 50 mg erlotinib in a patient with EGFR mutation positive NSCLC who developed a severe rash on full dose erlotinib. Rash is known to correlate with response and survival in patients treated with erlotinib. Our case suggests that in the presence of rash, dose reductions to "subtherapeutic" levels remain effective and may prevent unnecessary early treatment termination.
厄洛替尼越来越多地被用于治疗非小细胞肺癌。推荐剂量为每天 150 毫克，而低剂量的疗效数据尚不可用。我们描述了一例 EGFR 突变阳性非小细胞肺癌患者在使用全剂量厄洛替尼时出现严重皮疹，而使用 50 毫克厄洛替尼后肿瘤显著缩小的病例。皮疹与厄洛替尼治疗患者的反应和生存相关。我们的病例表明，在存在皮疹的情况下，减少剂量至“亚治疗”水平仍然有效，并可防止不必要的过早治疗终止。
